Richter Gedeon (RIG2.F)

Executive Summary

Richter Gedeon is a Hungary-based multinational pharmaceutical company with a core focus on women's healthcare and central nervous system (CNS) disorders. The company has a robust commercial portfolio, including the blockbuster drug cariprazine (Vraylar) for bipolar I disorder and schizophrenia, which drives significant revenue. Richter operates across over 100 countries and maintains a diversified pipeline of 34 drug candidates, spanning biosimilars and novel therapies. With a market cap of approximately $7.25 billion, the company demonstrates strong financial stability and consistent investment in R&D. The company's pipeline includes several late-stage assets that could provide near-term catalysts. An ongoing Phase 3 trial of cariprazine for schizophrenia (NCT03817502) is expected to complete in December 2026, with data readout anticipated in early 2027. Additionally, Richter's biosimilar denosumab (RGB-14-P) completed Phase 3 for postmenopausal osteoporosis in 2023 and is likely under regulatory review, with a potential approval decision in 2026-2027. While the company faces generic competition in some mature markets, its focused therapeutic areas and expanding pipeline position it for sustainable growth. Richter's strong execution and strategic partnerships further support its competitive edge in the biotech sector.

Upcoming Catalysts (preview)

• Q1 2027Phase 3 Data Readout for Cariprazine in Schizophrenia (NCT03817502)80% success
• 2026-2027Regulatory Decision for Biosimilar Denosumab (RGB-14-P) in Postmenopausal Osteoporosis70% success